RPT-Medtech stocks benefit as drug-pricing scrutiny intensifies

NEW YORK, Dec 2 (Reuters) - Investors have been moving into medical device shares as a safer play in the healthcare sector amid concerns that intensifying scrutiny over high U.S. prescription drug prices will continue to weigh on pharmaceutical and biotech stocks.